The recent ToGA trial showed that the addition of trastuzumab therapy to chemotherapy significantly improves survival of patients with HER2-expressing advanced or metastatic GC, underscoring the importance to accurately identify patients eligible for this treatment [3]. Here, ERBB2 is linked to gastric cancer.